AFT Pharmaceuticals (ASX.AFP) has extended its Maxigesic commercialisation agreements, adding the Polish company Mercapharm Sp.z.o.o and the Greek Company Vianex S.A. as partners for the patented combination pain killer.
These agreements cover territories with a total population of more than 48.5 million people.
Vianex has licensed the rights to the Maxigesic IV intravenous product in the Greek market while Mercapharm’s new distribution agreement covers the tablet, oral liquid, hot drink, fast-dissolve and dry powder sachets as well as Maxigesic IV.
Managing Director, Dr Hartley Atkinson. says with the addition of Poland to the oral Maxigesic line AFT has now secured partners in 23 out of the 27 EU member states, while MaxigesicIV now has partners for 22 member states.
Mercapharm has an excellent understanding of the Polish market and with a population of 37.9 million (2019) we believe the country offers great potential for Maxigesic,” he said.
Dr Atkinson said the new partner in Greece was well placed to drive the adoption of Maxigesic.
“Vianex is a strong local partner with excellent knowledge of the Greek hospital pharmaceutical sector and their strong sales reflect this,” Dr Atkinson said.
Maxigesic IV is expected to receive regulatory approval in Poland and Greece in mid- 2022 with sales expected to begin shortly thereafter.
Maxigesic IV (Paracetamol 1000mg+ Ibuprofen 300mg solution for infusion) is an intravenous formulation developed as a line extension to Maxigesic tablets, for use post-operatively in hospitals when patients cannot take a medicine orally.
A major Phase 3 clinical trial conducted in the USA found that Maxigesic IV provided significantly better pain relief than either paracetamol (acetaminophen) IV or ibuprofen IV alone in the same doses
Following on from the registration of Maxigesic IV in Australia and New Zealand in mid- 2019, AFT has now licensed the medication in more than 90 countries. Meanwhile, the tablet form of Maxigesic has been licensed in more than 125 countries.
